Dr. Amy Heimberger on Immunotherapeutics in the Context of Glioblastoma
Amy Heimberger, MD, professor in the Department of Neurosurgery, University of Texas MD Anderson Cancer Center, talks about immunotheraputics in the context of glioblastoma (GBM).
Amy Heimberger, MD, professor in the Department of Neurosurgery, University of Texas MD Anderson Cancer Center, talks about immunotheraputics in the context of glioblastoma (GBM). Heimberger says the mechanisms that glioblastoma tumors use for suppression are much more heterogenous than other tumors. She said because of this, oncologists are now studying the effects of targeted the key hubs of tumor-mediated immune suppression.
Heimberger says one target of interest for oncologists is in the secreted protein FGL2. FGL2 is secreted by GBM and regulated several mechanisms of immune suppression. Heimberger says that by targeting FGL2, treatment could be more significant for GBM patients.
In SCLC, Upfront BMS-986012 Plus Nivolumab/Chemotherapy Has Potential
September 13th 2024The addition of BMS-986012 to nivolumab and chemotherapy showed promising signals of improved overall survival in patients with extensive-stage small cell lung cancer compared to nivolumab and chemotherapy alone.
Read More
Consolidation Durvalumab Shows Consistent Survival Improvements in LS-SCLC Subgroups
September 13th 2024The ADRIATIC trial found that consolidation therapy with durvalumab improved progression-free survival and overall survival in patients with limited-stage small cell lung cancer, regardless of prior prophylactic cranial irradiation or concurrent chemoradiotherapy use.
Read More
